Colorectal Cancer Clinical Trial
— GEPOCOfficial title:
Geriatric Assessment and Intervention in Older Patients Undergoing Surgery for Colorectal Cancer
NCT number | NCT03719573 |
Other study ID # | 123 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | February 21, 2019 |
Est. completion date | May 10, 2022 |
Verified date | August 2022 |
Source | Herlev and Gentofte Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The GEPOC study investigates the effect of comprehensive geriatric assessment and intervention for frail older patients (65 years or older) undergoing elective surgery for colorectal cancer. the geriatric intervention will be pre- and postoperative. included in the intervention is an exercise intervention. The main aim of the study us to see if the functional decline in this group can be reduced.
Status | Completed |
Enrollment | 67 |
Est. completion date | May 10, 2022 |
Est. primary completion date | May 10, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years and older |
Eligibility | Inclusion Criteria: - elective surgery for colorectal cancer - frail - ability to read and speak danish (informed concent) Exclusion Criteria: - any physical condition that hinder physical exercise (eg. no legs) - not able to concent |
Country | Name | City | State |
---|---|---|---|
Denmark | Herlev and Gentofte Hospital | Herlev | Region H |
Lead Sponsor | Collaborator |
---|---|
Herlev and Gentofte Hospital | University of Copenhagen, Velux Fonden |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 30-second chair stand test (30s-CST) | functional test measuring lower body strength | baseline to 14 weeks after surgery | |
Secondary | physical function and capacity - 6-minute-walk-test | 6-minute-walk-test | baseline to 14 weeks after surgery | |
Secondary | physical function and capacity - hand grip strength | hand grip strength | baseline to 14 weeks after surgery | |
Secondary | physical function and capacity - 6-meter gait speed | 6-meter gait speed | baseline to 14 weeks after surgery | |
Secondary | Patient reported Quality of Life: EORTC | EORTC European Organisation for Research and Treatment of Cancer questionnaire C30 (30-126 points where 30 is the worst) | baseline to 14 weeks after surgery | |
Secondary | Patient reported Quality of Life: EORTC ELD14 | EORTC European Organisation for Research and Treatment of Cancer questionnaire conjoined with ELD14 (Elderly Cancer Patient module) (14-54 points where 54 is the worst) | baseline to 14 weeks after surgery | |
Secondary | Quality of recovery after surgery: questionnaire | Measured with the questionnaire: Quality of Recovery - 15 questionnaire (0-150 points where 0 points is the worst) | 1 day before surgery (baseline) to 3 days after surgery | |
Secondary | body composition | measured by Bioimpedance assessment | baseline to 14 weeks after surgery. | |
Secondary | body composition | measured by dual-energy x-ray absorptiometry | baseline to 14 weeks after surgery. | |
Secondary | inflammatory biomarker - CRP | the concentration of CRP (CRP C-reactive Protein) | baseline to 14 weeks after surgery | |
Secondary | inflammatory biomarker - Interleukin 6 | the concentration of interleukin 6 | baseline to 14 weeks after surgery | |
Secondary | inflammatory biomarker YKL-40 | the concentration of YKL-40 (YKL-40 is also known as Chitinase-3-like protein 1) | baseline to 14 weeks after surgery | |
Secondary | inflammatory biomarkers immuno-oncology | the concentration of 92 proteins associated with immuno-oncology (OLink) | baseline to 14 weeks after surgery | |
Secondary | sarcopenia biomarker GDF-11 | the concentration of GDF-11 (GDF Growth Differentiation Factor) | baseline to 14 weeks after surgery | |
Secondary | sarcopenia biomarker GDF | the concentration of GDF-15 (GDF Growth Differentiation Factor) | baseline to 14 weeks after surgery | |
Secondary | Postoperative complications | Measured with Clavien Dindo classification (grade I-V where grade V is death) | 30 days + 90 days | |
Secondary | readmission | Number of patients being readmitted to hospital within 30 + 90 days after operation for colon surgery. | 30 days after surgery and 90 days after surgery | |
Secondary | survival | number of survivors after surgery | 10 years | |
Secondary | mortality | number of patients death | baseline to 3 months | |
Secondary | number of patients to start up of adjuvant chemotherapy after surgery. | according to guidelines, if physical condition allows it (and patient accepts it). | 14 weeks | |
Secondary | start up time of adjuvant chemotherapy after surgery | measured in days (if relevant) | 14 weeks | |
Secondary | number of series of adjuvant chemotherapy | 14 weeks | ||
Secondary | doses of adjuvant chemotherapy | 14 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |